Patient-Derived Xenografts (PDX)

Charles River defines patient-derived tumor grafts as explants established as models at low passage numbers (average of 6 passes removed from patient). They have not been grown in plastic or propagated as cell cultures.

Establishing xenograft tumor models from patient-derived tumor tissue (PDTT) at low passage is believed to conserve original tumor characteristics such as heterogeneous histology, clinical biomolecular signature, malignant phenotypes and genotypes, tumor architecture and tumor vasculature. Based on this prevalent hypothesis, patient-derived tumor grafts are believed to offer relevant predictive insights into clinical outcomes when evaluating the efficacy of novel cancer therapies.

Tumor Model Compendium
Compendium navigation tutorials:

Visit our PDX Compendium »

By leveraging the wealth of information that we have on each tumor model, we can help you select the best one for your studies.

Need help selecting a model? »

We currently have more than 400 fully characterized proprietary patient-derived xenografts (PDXs) in our portfolio, which represent all major histotypes and tumors, and provide extensive background and characterization.

PDX Compendium Poster

Our PDX portfolio includes:

  • Subcutaneous, orthotopic and disseminated models
  • Extensive molecular and pharmacological characterization, and complete records on patients‘ pretreatment
  • Integrated approach using the same PDX models and/or the corresponding cell line
  • 2D/3D screening assays and subsequent in vivo studies
  • Identification of biomarkers, which predicts tumor sensitivity of compounds
  • Constant addition of new models, which are continuously established through international collaborations with major hospitals and universities

To learn more about our offerings, including molecular information, visit our PDX Compendium.

You may also be interested in...

Touchscreen image

Humanized Mouse Models Webinar

View our webinar about our studies on both PDX and traditional xenograft mouse models, evaluating the response to immune checkpoint inhibitors in humanized mouse models.

Imaging

Our range of imaging modalities can dramatically increase the efficiency and significantly enhance the value of your in vivo study.

PDX Models Webinar

View our webinar to learn how to incorporate these models into your IO and non-IO programs.